Navigation Links
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Date:7/31/2009

tical company, is building a diversified portfolio of oncology products that represents a comprehensive approach to extend and enhance the lives of patients with cancer. Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio includes a number of promising investigational and marketed compounds. The therapeutic portfolio in the United States includes two marketed products: TREANDA, which is approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen and TRISENOX((R)) (arsenic trioxide) injection, approved for the treatment of patients with relapsed or refractory acute promyelocytic leukemia.

In Europe, Cephalon markets three additional oncology products in 19 countries.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key affiliates are
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
3. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
4. Cephalons New Product Launches Pace Record 2008 Sales
5. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
6. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
7. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
8. Cephalon, Inc. to Webcast Analyst Day
9. Cephalon Reports Another Strong Quarter
10. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
11. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Pearl's Premium Ultra Low Maintenance Lawn Seed ... seed this week with the release of their Pearl's ... the fact that it is time to plant now ... , As of the date 6/4/13, Pearl's Premium had ... experts and the media including: The National Gardeners ...
(Date:9/22/2014)... job it is to stop bleeding, are very simple. ... "feel" the physical environment around them, researchers at Emory ... surfaces with greater stiffness by increasing their stickiness, the ... other components of the clotting system, the researchers found. ... for, in that they are able to sense the ...
(Date:9/22/2014)... to create a highly sensitive chemical sensor based on ... unique electronic properties that the researchers were able to ... 300 times. , The study is available online in ... Amin Salehi- Khojin, asst professor of mechanical and industrial ... and Bijandra Kumar, post doc where they are doing ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Topical BioMedics, ... those in pain end their suffering, restoring hope an ... model. This is only possible because of the innovative ... healing cream technology a reality. , The company ... NY, by Lou Paradise (president, chief of research, and ...
Breaking Biology Technology:Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6
... West Central Wisconsin Workforce Resource is inviting representatives ... Synergy Conference titled "Positioning for Economic Growth." , ,The conference ... a.m. to 5 p.m. and Sept. 21 from 8 a.m. ... Memorial Student Center . , ,Although some speakers have ...
... - Mithridion, Inc. , a biopharmaceutical startup that is ... secured $296,800 in federal grants to evaluate tests for drug ... Institute on Aging , a branch of the U.S. ... the feasibility of the tests. If successful, the company will ...
... Wis. - The recent decision by a young researcher ... some of the financial consequences of the same-sex union debate ... and nanotechnology researcher, has won $3.4 million in grants since ... year, he will take his knowledge and research with him ...
Cached Biology Technology:Conference to address small town development 2Mithridion wins grants for Alzheimer's research 2Mithridion wins grants for Alzheimer's research 3Departure of nanotech researcher stings UW 2Departure of nanotech researcher stings UW 3
(Date:9/21/2014)... to what was previously thought, newborn immune T cells ... to bacteria, according to a new study led by ... differently to that of adults, babies may still be ... study published in the journal Nature Medicine . ... different types of immune cells, including neutrophils which play ...
(Date:9/19/2014)... today by researchers from several Harvard University labs ... experienced and aspiring researchers with the intellectual raw ... made from soft, flexible materials. , With the ... other advances in manufacturing technology, soft robotics is ... drawn from conventional rigid robot design, but working ...
(Date:9/19/2014)... Imagine you are a species which over thousands of years ... exposed to a substance that makes the cold dangerous for ... Enchytraeus albidus , and the cold provoking substance, called ... cosmetics. , Nonylphenol is suspected of being a endocrine disruptor, ... It inhibits the worm,s ability to protect the cells in ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... were not the only ones with visions of sugar plums ... a new research report published in the January 2010 issue ... ), a team of scientists from the University of Texas ... compound from licorice root (glycyrrhizin from Glycyrrhiza glabra ) ...
... DALLAS Jan. 4, 2010 An experimental drug currently ... fighting the brain cancer glioblastoma and prostate cancer, researchers at ... The drug,s actions, observed in isolated human cells in ... encouraging because they attacked not only the bulk of the ...
... origin of the Devil Facial Tumour Disease (DFTD) that has ... scientists has discovered. Devil Facial Tumour Disease (DFTD) ... was first reported in 1996. It is spread by biting ... large tumours, mostly on the face and mouth, which often ...
Cached Biology News:A trip to the candy store might help ward off rare, but deadly infections 2Experimental drug shows promise against brain, prostate cancers 2Nervous culprit found for Tassie devil facial tumor disease 2
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... (Thr183/Tyr185) Antibody, Catalog #9251, 200 ul ... 200 ul SAPK/JNK Cell Extracts, Catalog ... HRP-linked Antibody, Catalog #7074, 100 ul ...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: